Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korean Government Raises H1N1 Alert Level to Highest Yet; Forms Anti-disaster Team

This article was originally published in PharmAsia News

Executive Summary

SEOUL - In a move to counter the fast-paced spread of the A/H1N1 virus, which is taking on epidemic proportions now in South Korea, the government on Tuesday raised its national health alert to the highest "Red" level

You may also be interested in...



Korea's Green Cross Seeks To Unveil Injectable Flu Antiviral Peramivir Even Before KFDA Approval

SEOUL - With or without an approval from Korea FDA, South Korea's vaccine producer Green Cross is gearing up to launch its version of injectable antiviral peramivir, which was developed by BioCryst Pharmaceuticals for treatment of influenza

Korea's Green Cross Seeks To Unveil Injectable Flu Antiviral Peramivir Even Before KFDA Approval

SEOUL - With or without an approval from Korea FDA, South Korea's vaccine producer Green Cross is gearing up to launch its version of injectable antiviral peramivir, which was developed by BioCryst Pharmaceuticals for treatment of influenza

Korean Drug Regulators Raid Roche Korea, Search For Evidence On Tamiflu Stockpiling

SEOUL - An investigative team organized by the Korean FDA, and headed by a state prosecutor, raided the Seoul office of Roche on November 5 to search for and seize any documents that would confirm suspicions that Roche Korea might have helped some companies stockpile the antiviral drug Tamiflu

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel